Skip to main
GMDA
GMDA logo

GMDA Stock Forecast & Price Target

GMDA Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 71%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Gamida Cell is a clinical-stage biopharmaceutical company with a promising immunotherapy pipeline utilizing NAM expansion technology, and boasts a strong financial position with $60.4 million cash on hand, only $81.4 million in convertible senior notes due at YE:24, and the potential for an additional $23.58 million from 17.467 million warrants with a $1.35 strike price. With a decreased projected market cap of $338 million and 151.5 million diluted YE:24E shares, the company's stock is currently valued at $2, indicating potential for growth in the future.

Bears say

Gamida Cell is facing several risks that contribute to the negative outlook, including potential underperformance of Omisirge sales, the possibility of GDA-201 failing in clinical trials, and the potential need for additional funding. Despite maintaining an Overweight rating, recent financials and updated metrics have led to a decreased price target of $2, reflecting a lower projected enterprise value of $437 million and anticipated dilution from ATM offerings. With slower than expected Omisirge launch and a lowered forecast of just $1.68 million in revenue for this year, Gamida Cell is exploring strategic funding options to fully support the launch. Additionally, while preliminary data for GDA-201 in Non-Hodgkin Lymphoma showed promise with a 40% ORR, full Phase I data is not expected until 1Q:24 and the company ended 3Q:23 with only $60.4 million in cash, enough to fund operations until 2Q:24.

GMDA has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 71% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Gamida Cell Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Gamida Cell Ltd (GMDA) Forecast

Analysts have given GMDA a Buy based on their latest research and market trends.

According to 7 analysts, GMDA has a Buy consensus rating as of Jul 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Gamida Cell Ltd (GMDA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.